ReviewPediatric diabetes2016
A Swedish approach to the prevention of type 1 diabetes.
Review in Pediatric diabetes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Socioeconomic deprivation results in high rates of diabetic ketoacidosis at type 1 diabetes diagnosis in England: A multicentre observational study.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Health economic considerations of screening for early type 1 diabetes.Diabetes, obesity & metabolism · 2025Review
- Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles.Diabetes care · 2024Article
- Refining the Definition of Stage 1 Type 1 Diabetes: An Ontology-Driven Analysis of the Heterogeneity of Multiple Islet Autoimmunity.Diabetes care · 2023Article
- Islet autoantibody screening in at-risk adolescents to predict type 1 diabetes until young adulthood: a prospective cohort study.The Lancet. Child & adolescent health · 2023Article
- Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study.The lancet. Diabetes & endocrinology · 2022Article
- Childhood Height Growth Rate Association With the Risk of Islet Autoimmunity and Development of Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2022Article
- Progression of type 1 diabetes from latency to symptomatic disease is predicted by distinct autoimmune trajectories.Nature communications · 2022Article
- Islet Autoimmunity and HLA Markers of Presymptomatic and Clinical Type 1 Diabetes: Joint Analyses of Prospective Cohort Studies in Finland, Germany, Sweden, and the U.S.Diabetes care · 2021Article
- Diabetic Ketoacidosis at Manifestation of Type 1 Diabetes in Childhood and Adolescence—Incidence and Risk Factors.Deutsches Arzteblatt international · 2021Article
- Simulating Screening for Risk of Childhood Diabetes: The Collaborative Open Outcomes tooL (COOL).AMIA ... Annual Symposium proceedings. AMIA Symposium · 2021Article
- Imputing Longitudinal Growth Data in International Pediatric Studies: Does CDC Reference Suffice?AMIA ... Annual Symposium proceedings. AMIA Symposium · 2021Article
- Characterization of plasma lipidomics in adolescent subjects with increased risk for type 1 diabetes in the DiPiS cohort.Metabolomics : Official journal of the Metabolomic Society · 2020Article
- The science and medicine of human immunology.Science (New York, N.Y.) · 2020Review
- Parent Preferences for Delaying Insulin Dependence in Children at Risk of Stage III Type 1 Diabetes.Diabetes technology & therapeutics · 2020Article
- Decreased HLA-DQ expression on peripheral blood cells in children with varying number of beta cell autoantibodies.Journal of translational autoimmunity · 2020Article
- Maternal obesity as a risk factor for early childhood type 1 diabetes: a nationwide, prospective, population-based case-control study.Diabetologia · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundThe autoimmune destruction of beta cells, resulting in clinical type 1 diabetes, may start early in life and last for several months or years. During this period of time, we have an opportunity to try to prevent or delay further beta-cell destruction and clinical onset of type 1 diabetes.
objectivesOngoing prediction and prevention studies in Skåne, Sweden are described.
methodsDuring September 2000 to August 2004, 35 000 children were screened at birth for genetic type 1 diabetes risk in the Diabetes Prediction in Skåne Study (DiPiS). In August 2004, the screening continued within the Enviromnental Determinants of Diabetes in the Young study (TEDDY). In the clinical trial Diabetes Prevention - Immune Tolerance (DiAPREV-IT), children with multiple islet autoimmunity have been included to investigate if immune tolerance with Alum-formulated GAD65 may prevent further beta-cell loss.
resultsIn DiPiS and TEDDY, a large number of children are followed in order to find the factors that trigger the autoimmune process leading to type 1 diabetes. Children followed in the studies develop diabetes at an early stage of disease, with few symptoms and a low frequency of diabetes ketoacidosis. DiAPREV-IT is still blinded and results will be available in December 2016.
conclusionLarge prospective studies will be needed to understand the complex process leading to type 1 diabetes. Secondary prevention may be possible in children with islet autoimmunity, but the studies are complicated by the variability of glucose metabolism and beta-cell loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.